“This is a special virtual issue comprised of the Editors’ choices of the most original and most significant scientific findings published in the preceding three issues (October 2013-December 2013) of JPharmSci®.” These papers will be freely available until March 31st 2014.
This quarter we feature Tetsuya Terasaki’s comments for the paper he chose:
" Pharmacokinetic study of adenosine diphosphate-encapsulated liposomes coated with fibrinogen γ-chain dodecapeptide as a synthetic platelet substitute in an anticancer drug-induced thrombocytopenia rat model " pages 3852-3859, DOI: 10.1002/jps.23692
For the treatment of thrombocytopenia, platelets are transfused to the patients. As the shelf life of platelets is very short (~ 5 days), significant efforts have been made to develop clinically applicable "artificial platelets" in the past 50 years. Recently, Japanese researchers have developed adenosine diphosphate-encapsulated liposomes coated with fibrinogen γ-chain dodecapeptide [H12-(ADP)-liposome] as a new candidate of "artificial platelets". In this paper, the authors investigated pharmacokinetics of H12-(ADP)-liposome in busulphan-induced thrombocytopenic rats and normal rats. This work provides important findings for the understanding of PK/PD of H12-(ADP)-liposome in the patients.